BackgroundAromatase inhibitor-induced arthralgia (AIA) is a frequent adverse effect of endocrine therapy in breast cancer survivors, often leading to treatment modification or discontinuation. Non-pharmacological interventions have been proposed to manage AIA, but evidence remains fragmented.ObjectiveTo synthesize recent randomized controlled trials (RCTs) evaluating the efficacy of non-pharmacological interventions for AIA.MethodsA systematic search of PubMed, Scopus, and… Continue reading Effectiveness of Non-Pharmacological Interventions for Hormone Therapy-Induced #Hand #Arthralgia in Breast Cancer Patients: A Systematic Review
Category: Oncology
Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients
Purpose: Selective Internal Radiotherapy (SIRT) is an established treatment option for hepatocellular carcinoma (#HCC ). However, a major complication is radioembolization-induced liver disease (REILD).Methods: This retrospective study, analyzed patients treated with SIRT for HCC to identify clinical factors associated with REILD and to predict treatment response. Machine learning (#ML ) methods were applied to two… Continue reading Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients
Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer
Background: Among the approved therapies for metastatic hormone-sensitive #prostate #cancer (mHSPC), abiraterone and docetaxel are administered concomitantly with #corticosteroids . This study evaluated the association between corticosteroid use and risk of adverse events among patients with mHSPC.Methods: We conducted an observational cohort study among patients ≥ 65 years of age who were enrolled in Medicare… Continue reading Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer
Characteristics and outcomes of patients with #HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
Background: Atezolizumab plus bevacizumab (atezo+bev) is a standard-of-care 1L treatment for unresectable hepatocellular carcinoma (uHCC). Understanding its adoption and use, clinical outcomes, and subsequent therapies are needed.Methods: This retrospective cohort study included 550 patients with u #HCC in the US who initiated 1L atezo+bev between June 2020 and April 2023. Medical records were abstracted to… Continue reading Characteristics and outcomes of patients with #HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
Effect of #statin use on prognostic outcomes in #hepatocellular carcinoma following #liver surgery: a systematic review and meta-analysis
Hepatocellular carcinoma (HCC) recurrence remains a significant clinical challenge, even among patients who undergo surgical treatment. Although statins exhibit anticancer properties through several biologically plausible mechanisms, robust clinical evidence supporting their role in preventing HCC recurrence is still limited. This meta-analysis aimed to evaluate the impact of statin use on the prognostic outcomes of patients… Continue reading Effect of #statin use on prognostic outcomes in #hepatocellular carcinoma following #liver surgery: a systematic review and meta-analysis
#Fasting boosts #breast cancer therapy efficacy via glucocorticoid activation
The majority of breast cancers are driven by oestrogen receptor-α (ERα) activation, and endocrine therapy represents the mainstay treatment for these patients1. However, resistance is common and tumours often progress after years of endocrine suppression2. Periodic fasting enhances the efficacy of standard endocrine therapy and delays acquired drug resistance, although the underlying mechanisms remain unclear3.… Continue reading #Fasting boosts #breast cancer therapy efficacy via glucocorticoid activation
#Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Cholangiocarcinoma (CCA) is a cancer that originates within the bile ducts. Traditionally considered to be a rare neoplasm, increased awareness of CCA alongside advancements in diagnosis and the rising prevalence of certain risk factors have contributed to a global increase in incidence and mortality. CCAs are highly heterogeneous from the clinical, histomorphological and molecular perspectives… Continue reading #Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Is there any role for #HBV pgRNA in #fibrosis and #HCC predisposition?
Aim: In this cohort, we aimed to study the evolution of pregenomic RNA (pgRNA) during treatment and compare it with other disease scores such as FIB-4 and PAGE-B.Methods: Eighty-eight HBeAg negative CHB who received long-term treatment with NAs were included. A quantitative HBV S antigen (HBsAg) assay was performed, and viral HBV DNA was quantified… Continue reading Is there any role for #HBV pgRNA in #fibrosis and #HCC predisposition?
#Statins and clinical outcomes in patients with advanced #hepatocellular carcinoma treated with #Atezolizumab plus #Bevacizumab
The impact of statins on patients receiving immune checkpoint inhibitors for advanced hepatocellular carcinoma (aHCC) remains unclear. This study aimed to evaluate whether statins influence overall survival (OS) and progression-free survival (PFS) in aHCC patients receiving Atezolizumab + Bevacizumab (A + B). ARTE is a prospectively maintained dataset of 305 aHCC patients treated with A… Continue reading #Statins and clinical outcomes in patients with advanced #hepatocellular carcinoma treated with #Atezolizumab plus #Bevacizumab
2 Medical News 